Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 12.83% | Hold | 565,000 | $73.02 | $41M | — | — |
| STXS - Stereotaxis | 6.72% | Hold | 13,680,554 | $1.58 | $22M | — | — |
| CYTK - Cytokinetics | 4.39% | Add +44.1% | 479,538 | $29.46 | $14M | +146,804 | +$3M |
| IDYA - Ideaya Biosciences | 4.19% | Add +4.2% | 499,820 | $26.98 | $13M | +20,000 | +$2M |
| RVMD - Revolution Medicines | 4.08% | Reduce −7.6% | 473,394 | $27.68 | $13M | −38,891 | −$600K |
| ASND - Ascendis Pharma A/S | 3.97% | Add +0.7% | 136,212 | $93.64 | $13M | +1,000 | +$687K |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.90% | Hold | 102,500 | $122.29 | $13M | — | — |
| Blueprint Medicines | 3.90% | Reduce −0.8% | 249,521 | $50.22 | $13M | −2,000 | −$3M |
| Merus | 3.56% | Add +26.0% | 484,870 | $23.58 | $11M | +100,000 | +$1M |
| XENE - Xenon Pharmaceuticals | 2.98% | Hold | 280,538 | $34.16 | $10M | — | — |
| Karuna Therapeutics | 2.78% | Add +25.4% | 52,873 | $169.09 | $9M | +10,700 | −$205K |
| NBIX - Neurocrine Biosciences | 2.58% | Reduce −1.3% | 73,615 | $112.50 | $8M | −1,000 | +$1M |
| DAWNGBX — | 2.24% | Add +15.7% | 586,463 | $12.27 | $7M | +79,363 | +$1M |
| SNDX - Syndax Pharmaceuticals | 2.07% | Add +1.7% | 458,373 | $14.52 | $7M | +7,500 | −$3M |
| DXCM - Dexcom | 1.96% | Hold | 67,552 | $93.30 | $6M | — | — |
| Kalvista Pharmaceuticals | 1.81% | Reduce −0.9% | 605,532 | $9.63 | $6M | −5,500 | +$332K |
| 2seventy Bio | 1.76% | Add +191.6% | 1,447,465 | $3.92 | $6M | +951,049 | +$650K |
| ATRC - Atricure | 1.71% | Hold | 125,529 | $43.80 | $5M | — | — |
| Morphic | 1.65% | Add +12.1% | 231,748 | $22.91 | $5M | +25,000 | −$7M |
| KURA - Kura Oncology | 1.56% | Add +53.9% | 550,784 | $9.12 | $5M | +193,000 | +$1M |
| AXGN - Axogen | 1.46% | Add +181.8% | 935,894 | $5.00 | $5M | +603,791 | +$2M |
| BCRX - Biocryst Pharmaceuticals | 1.44% | Add +14.6% | 652,000 | $7.08 | $5M | +83,000 | +$610K |
| TNDM - Tandem Diabetes Care | 1.43% | Add +100.6% | 220,708 | $20.77 | $5M | +110,708 | +$2M |
| NRIX - Nurix Therapeutics | 1.36% | Hold | 556,695 | $7.86 | $4M | — | — |
| ALEC - Alector | 1.27% | Reduce −1.6% | 628,938 | $6.48 | $4M | −10,000 | +$236K |
| Mirati Therapeutics | 1.26% | Reduce −1.9% | 92,887 | $43.56 | $4M | −1,813 | +$625K |
| RCUS - Arcus Biosciences | 1.24% | Reduce −1.3% | 222,717 | $17.95 | $4M | −3,000 | −$587K |
| VKTX - Viking Therapeutics | 1.10% | Add +8.9% | 319,655 | $11.07 | $4M | +26,000 | −$1M |
| ARAY - Accuray | 1.03% | Hold | 1,222,358 | $2.72 | $3M | — | — |
| EWTX - Edgewise Therapeutics | 0.93% | Hold | 519,384 | $5.73 | $3M | — | — |
| Mediwound | 0.85% | Hold | 257,653 | $10.64 | $3M | — | — |
| IPSC - Century Therapeutics | 0.81% | Hold | 1,307,407 | $2.00 | $3M | — | — |
| BCYC - Bicycle Therapeutics | 0.76% | Hold | 122,200 | $20.09 | $2M | — | — |
| AMLX - Amylyx Pharmaceuticals | 0.70% | New | 122,547 | $18.31 | $2M | +122,547 | +$2M |
| PRCT - Procept Biorobotics | 0.69% | Add +741.3% | 67,300 | $32.81 | $2M | +59,300 | +$2M |
| CATBUSD - Astria Therapeutics | 0.69% | Add +131.5% | 295,493 | $7.46 | $2M | +167,840 | +$1M |
| AUTL - Autolus Therapeutics | 0.67% | Reduce −0.2% | 928,253 | $2.33 | $2M | −2,141 | −$52K |
| Keros Therapeutics | 0.65% | Add +38.4% | 65,961 | $31.88 | $2M | +18,300 | +$188K |
| LKFT - Galapagos | 0.65% | Add +14.2% | 60,175 | $34.55 | $2M | +7,500 | −$63K |
| Third Harmonic Bio | 0.60% | New | 300,000 | $6.39 | $2M | +300,000 | +$2M |
| BWAY - Brainsway | 0.54% | Reduce −14.4% | 432,181 | $4.04 | $2M | −72,500 | +$595K |
| Regulus Therapeutics | 0.47% | Hold | 1,111,049 | $1.37 | $2M | — | — |
| CMPS - Compass Pathways | 0.44% | New | 193,000 | $7.40 | $1M | +193,000 | +$1M |
| Cerevel Therapeutics | 0.42% | New | 62,200 | $21.83 | $1M | +62,200 | +$1M |
| Immunogen | 0.41% | New | 83,000 | $15.87 | $1M | +83,000 | +$1M |
| LRMR - Larimar Therapeutics | 0.40% | Reduce −6.6% | 327,373 | $3.95 | $1M | −23,000 | +$196K |
| Spruce Biosciences | 0.40% | Add +82.7% | 570,130 | $2.26 | $1M | +258,130 | +$618K |
| Mereo Biopharma Group | 0.39% | Reduce −4.6% | 962,513 | $1.29 | $1M | −46,500 | −$90K |
| Gossamer Bio | 0.38% | New | 1,476,052 | $0.8328 | $1M | +1,476,052 | +$1M |
| PRQR - Proqr Therapeutics | 0.38% | Hold | 940,582 | $1.30 | $1M | — | — |
| Macrogenics | 0.37% | New | 258,496 | $4.66 | $1M | +258,496 | +$1M |
| CGEM - Cullinan Oncology | 0.36% | New | 127,284 | $9.05 | $1M | +127,284 | +$1M |
| Adicet Bio | 0.34% | Hold | 797,054 | $1.37 | $1M | — | — |
| Iteos Therapeutics | 0.34% | Hold | 98,560 | $10.95 | $1M | — | — |
| Syros Pharmaceuticals | 0.33% | Hold | 265,878 | $3.95 | $1M | — | — |
| Sutro Biopharma | 0.31% | Add +16.6% | 283,079 | $3.47 | $982K | +40,300 | −$147K |
| Mersana Therapeutics | 0.29% | Reduce −9.5% | 734,038 | $1.27 | $932K | −76,807 | −$2M |
| Vigil Neuroscience | 0.29% | Hold | 172,308 | $5.39 | $929K | — | — |
| BHVN - Biohaven | 0.28% | Add +65.8% | 35,000 | $26.01 | $910K | +13,887 | +$405K |
| IMVT - Immunovant | 0.27% | New | 22,500 | $38.39 | $864K | +22,500 | +$864K |
| ACRV - Acrivon Therapeutics | 0.23% | Hold | 76,852 | $9.56 | $735K | — | — |
| Nevro | 0.17% | Hold | 28,000 | $19.22 | $538K | — | — |
| Neuronetics | 0.13% | Hold | 313,717 | $1.35 | $424K | — | — |
| Elevation Oncology | 0.09% | Hold | 450,000 | $0.6626 | $298K | — | — |
| Adaptimmune Therapeutics | 0.09% | Hold | 351,064 | $0.7800 | $274K | — | — |
| Masimo | 0.08% | Hold | 3,000 | $87.68 | $263K | — | — |
| Karyopharm Therapeutics | 0.08% | Hold | 192,678 | $1.34 | $258K | — | — |
| CMPX - Compass Therapeutics | 0.07% | Hold | 116,882 | $1.97 | $230K | — | — |
| Nextcure | 0.07% | Reduce −11.5% | 166,185 | $1.29 | $214K | −21,511 | −$123K |
| Compugen | 0.06% | Hold | 205,202 | $0.9300 | $191K | — | — |
| Spero Therapeutics | 0.05% | Hold | 125,000 | $1.21 | $151K | — | — |
| Kinnate Biopharma | 0.05% | Add +31.2% | 105,179 | $1.40 | $147K | +25,000 | −$96K |
| INGN - Inogen | 0.02% | Hold | 15,000 | $5.22 | $78K | — | — |
| Acelyrin | 0.02% | New | 7,300 | $10.17 | $74K | +7,300 | +$74K |
Showing top 50 of 74 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Iveric Bio | 6.59% | Exit | 0 | $39.34 | $24M | −612,975 | −$24M |
| Sage Therapeutics | 2.32% | Exit | 0 | $47.02 | $8M | −180,306 | −$8M |
| Dice Therapeutics | 1.62% | Exit | 0 | $46.46 | $6M | −127,585 | −$6M |
| Lyra Therapeutics | 0.41% | Exit | 0 | $4.11 | $1M | −361,084 | −$1M |
| Surface Oncology | 0.26% | Exit | 0 | $0.8700 | $957K | −1,100,000 | −$957K |
| Pardes Biosciences | 0.21% | Exit | 0 | $1.81 | $779K | −430,291 | −$779K |
| Medicenna Therapeutics | 0.09% | Exit | 0 | $0.4818 | $318K | −660,000 | −$318K |
| Holding | 0.05% | Exit | 0 | $1.41 | $197K | −140,000 | −$197K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2